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Purpose of review Pain is the most prominent symptom in osteoarthritis. Pain experience is a 
complex and multifactorial phenomenon. This review, therefore, offers a brief overview of 
the literature on factors from main pain dimensions and summarizes current evidence for 
identifying pain phenotypes in knee osteoarthritis. 
 
Recent findings Peripheral structural damage has been traditionally considered a source of 
pain and this has strengthened with MRI studies; however, a discordance between structural 
damage and pain severity suggests individual variations in pain presentation which may be 
determined by genetic, environmental (obesity), psychological and neurological factors.  
Each of the factors may play its role or intact with other factors to contribute to the variation 
which can partly explain the overall lack of treatment efficacy with the current ‘one-size-fits-
all’ treatment approach. Identifying pain phenotypes in knee osteoarthritis is promising to 
develop individualized treatments; however, the validity and reliability of osteoarthritis pain 
phenotypes have not been tested in clinical practice. 
 
Summary Given the heterogeneity of osteoarthritis pain, peripheral, psychological and 
neurological factors are considered key phenotypic dimensions in the identification of pain 
phenotypes. This new concept allows for patients’ stratification for clinical trials, thus 
providing the potential for individualized interventions in patients with osteoarthritis pain. 
 




Osteoarthritis (OA) is the most common form of joint disease worldwide affecting 9.6% of 
men and 18% of women aged more than 60 years [1]. It is a chronic and painful disease of 
the synovial joint and the most common cause of chronic disability [2]. Knees, hips and 
hands are the most commonly affected joints. Pain is the most prominent symptom of OA 
which drives patients to seek healthcare. Thus, OA represents an enormous health and 
economic burden on patients and societies.  
There are no proven strategies to prevent, slow, halt or reverse the OA progression. Current 
OA management is mostly palliative and focuses on pain relief. There is no single ideal 
medication for management of pain. ‘First-line’ agents, such as paracetamol and non-steroid 
anti-inflammatory drugs (NSAIDs), have only small to moderate efficacy, with >75% of 
patients reporting the need for additional symptomatic treatment [3]. Therefore, pain control 
remains a substantial unmet need in OA treatment.  
Furthermore, OA is a heterogeneous condition characterized by a complex and multifactorial 
nature [4]. This leads to a large variation in pain presentations and responses to OA 
treatment. Some studies have considered disease or structural progression to identify knee 
OA phenotypes with few reports on pain phenotypes [4]. The pain experience is a complex 
phenomenon affected by factors across multiple domains–peripheral, psychological, and 
neurological [5]. This complexity has hindered the identification of pain phenotypes in prior 
work. Peripheral structural damage in the knee has historically been thought to be the key 
origin of pain in knee OA; however, a weak association between radiographic structural 
damage and knee pain [6] raised the possibility of individual variations in pain presentation 
which may be mediated by genetic, environmental (obesity), psychological and neurological 
factors. The exact etiology and mechanisms of each factor contributing to OA pain are far 
less well known. This review, therefore, offers a brief review of the literature on these factors 
associated with OA pain and summarizes evidence for identifying pain phenotypes in knee 
OA. 
Factors associated with OA pain  
Genetic factors  
Robust inter-individual differences in pain experience are often observed in the clinical 
setting, raising the possibility that the inter-individual variability in the experience of pain 
4 
 
may be due to differences in pain sensitivity which is probably affected by underlying genetic 
factors [7]. Earlier twin and epidemiological studies have demonstrated that pain sensitivity 
per se is heritable [8, 9], although it has been suggested that a range of factors such as prior 
experience, expectation, and current mood modulate the experience of pain and these factors 
themselves are genetically mediated [10-13]. The estimates of heritability from studies range 
from 9% to 60% for different pain traits [10, 11, 14]. The heritability of knee pain was 
estimated at 44% in a sib-pair study from our group [15]. 
Research has been trying to search for genes that might predispose individuals to the 
development of chronic pain or experiencing greater pain sensitivity. There were two 
categories (linkage and candidate-gene studies) that the majority of studies have fallen into. A 
variety of genes identified have been shown to be tentatively associated with pain states [16, 
17]. As in other fields, there have been inconsistent associations in the replication across 
populations or across pain conditions. Other than the general reason for inconsistent results in 
genetic studies including sample size, pain definition, etc, the pain field struggles with the 
existence of complex pain phenotypes [16]. For example, pain conditions are quite 
heterogeneous even if one could identify genetic associations with specific pain conditions, 
such as low back pain, or there are a number of subcategories while investigating a broader 
category of clinical pain [7, 16]. Recent years have seen an explosion of genome-wide 
association study (GWAS) in the identification of risk alleles; however, GWAS in human 
pain has lagged behind than in other fields, for reasons such as difficulties in undertaking the 
quantitative phenotyping of this subjective phenomenon [18]. At present, there is only one 
adequately powered GWAS conducted for chronic widespread pain (CWP) [19]. 
Relative to numerous genomics studies in OA, only a few studies have examined genes that 
regulate OA-related pain so far. Currently, there are six genes identified with a possible 
association with pain in OA, as shown in Table 1. A common genetic variant of Val158Met 
in catechol-O-methyltransferase (COMT) gene which reduces the activity of the 
catecholamine degrading enzyme was identified to be associated with hip pain among those 
with hip OA [20]. Unfortunately, this SNP failed to be replicated for knee pain in an 
independent and adequately powered study [21]. Another gene SCN9A encoding the voltage-
gated Sodium Channel 1.7 (Nav1.7) that is essential for transmission of pain-related signals, 
was initially shown to associate with greater pain in a study with 578 OA patients [22], and 
held up in a larger cohort of replication study [23]. Some other candidate genes have been 
examined and have confirmed associations with OA-related pain, including transient receptor 
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potential cation channel subfamily V member 1 (TRPV1), P2X7 and proprotein convertase 
subtilisin/kexin type 6 (PCSK6) [24-26]. More recently, one of six SNPs in the neurokinin 1 
receptor (TACR1) has shown a nominally significant association with a decreased risk of 
symptomatic OA in discovery cohort and then replicated in four additional cohorts [27]. 
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Table 1 Genomics studies in osteoarthritis-related pain 
Studies SNP Gene Protein Function of protein Sample size (n) Ethnic group Source 
Initial 
study 
       
 rs4680 COMT Catechol-O-methyltransferase 
Degradation of catecholamine 
neurotransmitters such as norepinephrine 
and dopamine 
288 (radiographic hip OA) Caucasian [20] 
     171 (female radiographic hip OA) Caucasian  
 rs6746030 SCN9A 
Voltage-gated Sodium Channel 1.7 
(Nav1.7) 
Nociception signalling 578 (symptomatic OA) Caucasian [22] 
 rs8065080 TRPV1 
Transient receptor potential cation 
channel, subfamily V, member 1 
Thermosensitive channel 
7122 (3270 symptomatic knee OA 
and 3852 controls) 
Caucasian [24] 
     
4950 (1098 asymptomatic knee OA 
and 3852 controls) 
Caucasian  
 rs7958311 P2X7 P2X purinoceptor 7 
Ionotropic ATP-gated receptors, 
affecting pore formation in cell 
membranes  





 rs900414 PCSK6 
PACE4 (paired amino acid converting 
enzyme 4) 
Activating aggrecanases 
756 (600 symptomatic knee OA and 
156 asymptomatic knee OA) 
Caucasian [26] 
     
2742 (2068 symptomatic knee OA 
and 674 asymptomatic knee OA) 
Caucasian  
 rs11688000 TACR1 Neurokinin receptor 1 
Dopamine modulation in central nervous 
system 
1615 (1232 symptomatic OA and 
383 asymptomatic knee OA) 
Caucasian [27] 
     
2450 (1566 symptomatic OA and 
884 asymptomatic knee OA) 
Caucasian  
Replication rs4680 COMT Catechol-O-methyltransferase 
Degradation of catecholamine 
neurotransmitters such as 
norepinephrine and dopamine 
9556 (3934 symptomatic knee OA 
and 5622 controls) 
Caucasian [21] 
     
6781 (1159 asymptomatic knee OA 
and 5622 controls) 
Caucasian  
 rs6746030 SCN9A 
Voltage-gated Sodium Channel 1.7 
(Nav1.7) 
Nociception signalling 
1854 (1325 symptomatic OA or 
TKR and 529 asymptomatic OA) 
Caucasian [23] 





Pain in OA has been considered nociceptive pain, arising from peripheral local tissue damage 
[28]. Cartilage, the primary site of OA pathology, is aneural and avascular, so it cannot 
generate pain directly, raising the possibility that pain may come from other structures or 
chemicals released by cartilage [28]. By contrast, subchondral bone, adjacent periosteum, 
synovial membrane, periarticular ligaments and joint capsule are richly innervated with the 
nerve fibres transmitting peripheral input to spinal cord [29]. However, imaging studies have 
widely reported a discordance between radiographic severity of OA and pain severity [30]. A 
systemic review of the literature concluded that 15-76% of patients with knee pain had 
radiographic OA, and 15-81% of patients with radiographic OA had knee pain [31]. This 
discordance is often explained by the insensitivity of X-ray to discern underlying pathologies 
contributing to pain [32]. Some studies have examined the relationships between structures 
on MRI and knee pain and reported inconsistent results [32]. This is supported by a recent 
literature review describing only thirteen of twenty-one studies reporting statistically 
significant associations of MRI findings in OA and symptoms [33]. Table 2 summarizes the 
associations between structures detected on MRI and knee pain. Overall, the levels of 
evidence between structural features and pain are limited or conflicting, except for bone 
marrow lesions (BMLs) and effusion-synovitis which appear to have moderate levels of 
evidence supporting their relation to OA-related pain [30]. The lack of strong evidence of the 
association between structures detected on MRI scans or radiographs suggests that peripheral 












Table 2 Associations between knee structural factors detected by MRI and osteoarthritis pain 
Structures 
Evidence 
No Conflicting Limited Moderate Strong 
Cartilage defects  +    
Meniscal pathology  +    
Bone marrow lesions    +  
Bone attrition  +    
Osteophytes   +   
Effusion-synovitis    +  
Ligament tear   +   
Tibial bone size +     
Adapted from a systematic review by Yusuf et al. [35] 
Obesity  
Since the end of the last century, the relationship between obesity and chronic pain has 
attracted extensive investigation. There is a sizeable body of evidence to suggest that obesity 
and pain adversely impact each other, and obesity is predictive of worse functional and 
psychological status of chronic pain [36]. Based on a US study in one million people, 
individuals with overweight (body mass index (BMI), 25–29.9 kg/m2) reported 20% higher 
rates of pain, 68% higher for those BMIs of 30–34 kg/m2, 136% higher for those BMIs of 
35–39 kg/m2 and 254% higher for those BMIs of more than 40 kg/m2 compared to normal 
weight group [37]. Evidence from longitudinal studies suggests that obesity (even in 
childhood) is an important risk factor for the development of chronic pain, indicating that 
obesity is more likely a cause rather than a consequence of pain [38-40].  
It has long been assumed that potential mechanisms underlying the relationship between 
obesity and pain may be due to mechanical loading, especially for lower extremities. There is 
a linear increment of compressive loading across the joint as BMI increases. In knee OA, 
relative to those with overweight, people classified as class 1 or 2+ obesity have greater peak 
knee compressive forces [41]. Similarly, weight loss has been shown to be effective in 
reduction of knee joint forces [42]. Increased joint forces may result in an aberrant 
biomechanical environment; it is, therefore, not surprising to observe greater structural 
damage in the loading joint in obese individuals. The evidence of the role of inflammation 
involved in the link between obesity and pain is accumulating because adipose tissue has 
been recognized as an endocrine organ responsible for producing and releasing 
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proinflammatory cytokines and adipokines [43]. Recent studies have shown an increased 
level of cytokines and inflammatory markers, such as C-reactive protein (CRP), IL-6, tumor 
necrosis factor (TNF)-α and leptin in obese individuals [44, 45]. In addition, the release of 
inflammatory markers also can be triggered by the breakdown products from structures or 
tissues damages due to aberrant loading [46, 47]. Elevated levels of these biomarkers lead to 
enhancing pain severity and its change [48, 49], which in turn stimulate more inflammatory 
markers release [50]. Mounting evidence suggests that inflammation can lead to a lowering of 
excitation threshold and enhanced responses to suprathreshold stimuli of peripheral 
nociceptors (peripheral sensitization) and subsequently developing central nervous system 
sensitization with pain hypersensitivity and increased vulnerability to reporting more pain 
sites [30, 51].  
Psychological factors 
As in other pain conditions, psychological factors have been found to be crucial contributors 
to the OA pain experience [52]. Two critically important psychological factors—depression 
and catastrophizing have shown consistent associations with increased pain severity, reduced 
pain threshold, impaired physical function and poor response to treatment [52]. Psychological 
factors exert their effects on pain through multiple interactive pathways from behavioural, 
cognitive to neurophysiological (details can be found in the review [52]). Briefly, the 
mechanisms by which psychological factors contribute to pain may include dysfunction of 
pain processing in the central nervous system [53-55], genetic vulnerability [19] and 
cognitive influence [56]. In the context of OA, psychological health is implicated in the pain 
experience [57-59]. Furthermore, there is a growing body of evidence showing that patients 
with preoperative depression and pain catastrophizing are more likely to have higher pain 
scores after total knee replacement [60, 61]. However, causal effects are hard to be discerned 
due to bidirectional relationships between psychological factors and pain [62]. 
Neurological factors 
Various studies have shown pain in OA is neuropathic, reflecting that potential mechanisms 
of neuropathic pain are a consequence of the interrelation of peripheral and central 
sensitization mechanisms [63-65]. Joint injury and/or inflammation lead to the release of 
mediators into the joint which sensitize primary afferent nerves with a reduction in threshold 
and an amplification of responsiveness to suprathreshold stimuli of peripheral nociceptors 
(peripheral sensitization) [66-68]. As such, exaggerated responses to noxious mechanical 
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stimuli (primary hyperalgesia) can be evoked, and normally innocuous joint movement can 
evoke a painful response (allodynia) [30]. Increased peripheral neuronal activity further 
confers the alteration in pain processing by the central nervous system (central sensitization) 
including more responsive to peripheral input, an expansion of receptive filed of dorsal horn 
neurons as well as brain activation, sensitization and modification [34, 69]. Studies using 
quantitative sensory testing (QST) analyses and functional MRI have confirmed central 
sensitization in OA [65, 69]. The presence of central sensitization in OA may be predictive of 
more severe, longer duration and larger area of pain which does not respond to conventional 
analgesics [64]. 
Searching for pain phenotypes in OA 
There have been numerous attempts to identify OA phenotypes in order to better target this 
heterogeneous condition. In a systematic review including 24 studies to identify knee OA 
phenotypes, Dell’lsola et al [4] proposed that there are existing six phenotypes based on key 
variables extracted from prior studies: chronic pain (central sensitization mechanisms are 
prominent); inflammatory knee OA; metabolic syndrome; bone and cartilage metabolism; 
mechanical overload; minimal joint disease. More recently, Deveza et al [70] identified knee 
OA phenotypes and their clinical outcomes in a review with 34 observational studies. The 
author found that poor clinical outcomes were linked to pain sensitization, psychological 
distress, radiographic severity, BMI, muscle strength, inflammation and comorbidities. Poor 
structural outcomes were associated with gender, obesity and other metabolic abnormalities, 
inflammation and cartilage damage pattern. Although these distinct phenotypes clearly show 
the variability in OA mechanisms and may represent different subgroups to benefit from 
different treatments, it remains unclear about whether mechanisms of OA pathology and OA 
pain might differ and therefore they can be considered discrete entities separately [71]. From 
a clinical perspective, a phenotype based on OA pain traits would be more clinically 
meaningful than structural characteristics given the fact that there are no approved disease-
modifying drugs available and that there is a great discordance between pain intensity and the 
extent of structural damage. 
While there is no agreement on pain traits selected to identify pain phenotypes in OA, studies 
have identified pain phenotypes mostly based on a single pain dimension and cross-sectional 
study design [70]. Profiling psychological factors, pain sensitivity, comorbidities and obesity 
were the most common investigation in prior studies; however, there were few studies on 
structural factors and across multiple pain dimensions including the factors mentioned above. 
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To date, only one cross-sectional study by Kittelson et al [72] identified four pain phenotypes 
in knee OA across multiple pain dimensions, including higher levels of comorbidities; higher 
knee joint sensitivity; higher levels of psychological distress; and minimal joint disease and 
pain. Structural pathology in this study was assessed by radiograph, other MRI structural 
lesions associated with OA pain such as BMLs and effusion-synovitis were not profiled. This 
is of clinical relevance to early interventions as early MRI structural damage might be 
reversible. To shed light on this question, we recently identified pain phenotypes using a wide 
spectrum of factors including main pain dimensions (structural damage on MRI, BMI, 
comorbidities, psychological and neurological factors) [73]. Three distinct pain phenotypes 
were identified: Class 1 participants having a high prevalence of emotional problems and low 
prevalence of structural damage; participants in Class 2 had a high prevalence of structural 
damage and low prevalence of emotional problems, and Class 3 participant had a low 
prevalence of emotional problems and low prevalence of structural damage. Furthermore, we 
found that participants in Class 1 had greater pain severity and number of painful sites than 
those in Class 2 and 3 over 10.7 years. This may also suggest that the phenotypes reflect 
distinct clinical prognosis.  
Challenges in the identification of OA pain phenotypes 
There are some challenges in identifying OA or OA pain phenotypes due to their 
heterogeneity and lack of in-depth understanding of mechanisms by which etiological factors 
contribute to OA and pain, as such it seems hard to determine which factors most reflecting 
the disease pathophysiology should be profiled, and whether factors included may overlap 
with each other through other pathways. This raises an important question of whether 
phenotypes identified which really represent distinct patient subgroups whose clinical 
presentations, prognosis and response to treatments are different. There is no consensus 
regarding the core data or traits recommended for defining phenotypes in the OA field. 
Despite the important role of genetic factors in pain pathogenesis, focusing on modifiable 
factors in clinical practice could allow for potential intervention. In our opinion, therefore, 
core data from knee structural, psychological and neurological domains are essential in the 
identification of OA pain phenotypes. However, advanced imaging techniques (e.g. MRI) and 
QST are not routinely utilized in clinical research and practice due to the cost and 
practicality. This may hinder to define a multidimensional phenotype and limit the potential 
use of the phenotype to inform stratified care in the clinical setting. Cross-sectional study 
design in prior studies aimed at identifying OA pain phenotypes was unable to validate the 
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stability of the phenotypes and determine whether phenotypes are relevant to clinical 
outcomes including prognosis and treatment response.  
Individualized pain treatment based on phenotypes: are we there yet? 
Currently, therapeutic interventions for OA are palliative and primarily focus on alleviating 
pain [74]; however, treatment for the management of OA pain is problematic and mainly 
targets the peripheral joint and peripheral nervous system. NSAIDs have been a mainstay 
treatment for OA pain, but the efficacy of these has been proven to be only moderate [75]. 
Intra-articular glucocorticoid injections and joint replacement surgery also play a key part in 
the management of OA, both targeting the peripheral mechanism of pain [76, 77]. Failure to 
relieve OA pain through these treatments is frequently seen in the clinical settings; for 
instance, there are approximately 7-23% and 10-34% of patients having long-term pain after 
hip and knee replacement surgery [78, 79], suggesting that treatments targeting peripheral 
mechanisms are insufficient for those patients.  
Weight loss has been a focus in the treatment and management of OA pain. It has been 
demonstrated that weight loss in obese patients can reduce the risk of the development of 
symptomatic OA [80] and improve symptoms in OA patients [81]. There is a dose-response 
relationship between weight loss and pain improvement in people with symptomatic knee OA 
[82]. A combination of exercise and diet is recommended to achieve weight loss and a greater 
pain reduction [83].  
With the appreciation of increasing understanding of psychological and neurological factors 
in OA pain, interventions targeting pain catastrophizing, cognitive behavioural therapy and 
pain coping skills training have drawn great attention, although the results were mixed. Other 
pain management strategies are emerging including sleep interventions and pain education 
[84-86]. The treatments (e.g. antidepressants) designed to target the central nervous system 
have shown effects on pain improvement in patients with knee OA [87, 88]; however, central 
sensitization does not exist in all patients with OA pain. It is likely that subgroup with this 
feature may have a greater pain improvement.  
Recent reviews summarized the new therapeutic approaches for OA pain and highlighted the 
heterogeneous feature of OA pain [89, 90]. It is highlighted that treatments might be only 
effective for subsets patients with a specific phenotype. Targeting selected subgroup 
(phenotype) enables the development of more effective analgesic and reduces the suffering of 
ineffective treatments. Patients with a specific OA phenotype (such as BMLs) have received 
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targeted therapies [91]. Further, studies using stratification according to neuropathic pain 
mechanisms confirm the effectiveness in certain subgroups of patients, but there are no 
studies available targeting selected OA pain phenotype in the clinical practice [92]. 
Therefore, implementing individualized treatments into clinical setting based on phenotypes 
from the research community still need considerable efforts. 
In conclusion 
Despite the fact that pain in knee OA is multifactorial, peripheral, psychological and 
neurological factors are considered key phenotypic dimensions in the identification of pain 
phenotypes. Further understanding of these factors contributing to OA pain mechanisms will 
lead to the identification of pain phenotypes in OA patients, thus ultimately provide 
individualised interventions. 
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